188re-sss lipiodol

Small moleculeexperimental

Clinical trial activity

2 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2010 (NCT01126463)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiodepletion

    radiodepletion

Chemistry & pharmacology

Payload
188-rhenium

Oral

No

Parenteral

No

Topical

No

Also known as

  • 188re-sss lipiodol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05797870Phase 2Feb 15, 2024Center Eugene Marquis
NCT01126463Phase 1May 1, 2010Center Eugene Marquis, University of Rennes
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Center Eugene MarquisAcademic/Hospital2222010
University of RennesAcademic/Hospital1012010
2 organizations
Page 1 / 1